"Effect of Amniotic Bladder Therapy on Female Sexual Function of Patien" by Sophie Wittenberg, Emma Ross et al.
 

Effect of Amniotic Bladder Therapy on Female Sexual Function of Patients With Interstitial Cystitis/Bladder Pain Syndrome: Early 3-Month Report

Document Type

Article

Publication Date

5-2024

Publication Title

Journal of Gynecologic Surgery

Abstract

Objective: Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by many urologic symptoms, including urgency, frequency, and pelvic pain. While 3 of the current authors and other colleagues described the value of micronized amniotic membrane (AM) injection previously to improve lower urinary-tract symptoms in patients with IC/BPS, this study specifically evaluated intradetrusor injections of micronized AM for patients with IC/BPS and concurrent female sexual dysfunction (FSD). Materials and Methods: Eleven consecutive patients with symptoms recalcitrant to multiple other therapies received intradetrusor injections of 100 mg of micronized AM (Clarix Flo® BioTissue, Miami, FL, USA) diluted in 10 mL of 0.9% preservative-free sodium chloride. Results: All patients had severe IC/BPS symptoms at baseline, with an average Interstitial Cystitis Symptoms Index (ICSI) score of 20.9 ± 0.3 and an average Problem Index (ICPI) score of 16 ± 0.0 that decreased to 5.8 ± 1.4 and 4.4 ± 1.4, respectively, at 12 weeks after treatment. Additionally, sexual function, measured by the Female Sexual Function Index (FSFI), improved from 21.2 ± 6.5 to 27.8 ± 6.8 at 12 weeks. This coincided with a reduction of pain associated with intercourse from 8.4 ± 0.9 to 6.3 ± 1.2 at 12 weeks. Conclusions: Amniotic bladder therapy could be a valuable treatment for IC/BPS with FSD, based on these encouraging results at 12 weeks after treatment.

Volume

40

Issue

3

First Page

194

Last Page

199

DOI

10.1089/gyn.2023.00

Link to Full Text

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Abstract Views: 2
see details

Share

COinS